Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Aviptadil
2. Invicorp
3. Porcine Vasoactive Intestinal Octacosapeptide
4. Rlf-100
5. Zyesami
1. Guinea Pig Vip
2. Guinea Pig Vip Octacosapeptide
3. Vip, Human, Porcine, Rat Vip (28 Amino Acids)
4. 96886-24-7
5. Akos034834067
Molecular Weight | 3344.9 g/mol |
---|---|
Molecular Formula | C147H239N43O42S2 |
XLogP3 | -13.7 |
Hydrogen Bond Donor Count | 51 |
Hydrogen Bond Acceptor Count | 51 |
Rotatable Bond Count | 116 |
Exact Mass | 3343.7362760 g/mol |
Monoisotopic Mass | 3342.7329212 g/mol |
Topological Polar Surface Area | 1480 Ų |
Heavy Atom Count | 234 |
Formal Charge | 0 |
Complexity | 7510 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 31 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection. Biophore has successfully developed aviptadil and is backward integrated with in-house API.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biophore seeks DCGI Emergency Use Approval of Aviptadil for Covid-19
Details : Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection. Biophore has successfully developed aviptadil and is backward integrated with i...
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 11, 2021
Details:
Biophore has developed Aviptadil and is backward integrated with in-house API. The company has also informed that it will be commencing commercial production immediately after the approval is received.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biophore Applies For DCGI Approval for Emergency Use of Aviptadil to Treat COVID-19
Details : Biophore has developed Aviptadil and is backward integrated with in-house API. The company has also informed that it will be commencing commercial production immediately after the approval is received.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 11, 2021
Details:
RLF-100® (aviptadil acetate) restores barrier function at the endothelial/alveolar interface and thereby protects the lung and other organs from failure. It is under development for the potential treatment of acute and chronic lung disease.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RLF-100
Study Phase: Phase II/ Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RLF-100® (aviptadil acetate) restores barrier function at the endothelial/alveolar interface and thereby protects the lung and other organs from failure. It is under development for the potential treatment of acute and chronic lung disease.
Brand Name : RLF-100
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 17, 2023
Details:
Zyesami (aviptadil acetate) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyesami
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Relief Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 19, 2022
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Relief Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Zyesami (aviptadil acetate) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.
Brand Name : Zyesami
Molecule Type : Peptide
Upfront Cash : Undisclosed
December 19, 2022
Details:
APR-TD011 has potential for the treatment of wounds in epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders characterized by fragile skin and mucous membrane with severe blistering throughout the body.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyesami
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Relief Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 14, 2022
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Relief Therapeutics
Deal Size : $30.0 million
Deal Type : Agreement
Details : APR-TD011 has potential for the treatment of wounds in epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders characterized by fragile skin and mucous membrane with severe blistering throughout the body.
Brand Name : Zyesami
Molecule Type : Peptide
Upfront Cash : Undisclosed
November 14, 2022
Details:
RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide (“VIP”) consisting of 28 amino acids. The reported data demonstrated high purity levels at six months at all temperatures tested, including at refrigerated and room temperature environments.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RLF-100
Study Phase: Phase II/ Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (aviptadil)
Details : RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide (“VIP”) consisting of 28 amino acids. The reported data demonstrated high purity levels at six months at all temperatures tested, including at refrigerated and room temperatur...
Brand Name : RLF-100
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 07, 2022
Details:
RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids, is under development for certain acute and chronic lung diseases, including pulmonary sarcoidosis.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RLF-100
Study Phase: Phase II/ Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids, is under development for certain acute and chronic lung diseases, including pulmonary sarcoidosis.
Brand Name : RLF-100
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 03, 2022
Details:
Zyesami (aviptadil acetate) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyesami
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2022
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Declines Emergency Use Authorization for Zyesami® (Aviptadil) for Subgroup of Patients With C...
Details : Zyesami (aviptadil acetate) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.
Brand Name : Zyesami
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 01, 2022
Details:
ZYESAMI (aviptadil), is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.
Lead Product(s): Aviptadil Acetate
Therapeutic Area: Psychiatry/Psychology Brand Name: Zyesami
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI...
Details : ZYESAMI (aviptadil), is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.
Brand Name : Zyesami
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 10, 2022
Details:
The primary endpoint (90 day 6-category ordinal score) was not supportive (OR 1.10; 0.79 – 1.54; p=0.56), and 90-day mortality secondary endpoint was also not supportive with 37% mortality in Zyesami (aviptadil) group vs 36% in the placebo group; HR 1.04 (0.77-1.41); p=0.79.
Lead Product(s): Aviptadil Acetate,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyesami
Study Phase: Phase IIIProduct Type: Peptide
Sponsor: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Lead Product(s) : Aviptadil Acetate,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The primary endpoint (90 day 6-category ordinal score) was not supportive (OR 1.10; 0.79 – 1.54; p=0.56), and 90-day mortality secondary endpoint was also not supportive with 37% mortality in Zyesami (aviptadil) group vs 36% in the placebo group; HR 1....
Brand Name : Zyesami
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 25, 2022
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?